Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction

The American Journal of Cardiology

Volumn 72, Issue 2, 1993, Pages 154-161

  Oldridge, Neil ^a   Furlong, William ^a   Feeny, David ^a   Torrance, George ^a   Guyatt, Gordon ^a   Crowe, Jean ^a   Jones, Norman ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; COLESTIPOL; MEVINOLIN; PROPRANOLOL;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH SERVICE; HEART REHABILITATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RESOURCE ALLOCATION; SMOKING CESSATION; SURVIVAL RATE;

CANADA; CHI-SQUARE DISTRIBUTION; COMPARATIVE STUDY; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH SERVICES; HUMAN; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0027162367     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(93)90152-3     Document Type: Article

References (34)

1. Cardiac rehabilitation after myocardial infarction: combining data from randomized clinical trials
2. An overview of randomized trials of rehabilitation with exercise after myocardial infarction
3. Risk factor modification after myocardial infarction
4. Medical costs of coronary artery disease in the United States
5. Cardiac rehabilitation services
6. Cardiac rehabilitation participation predicts lower rehospitalization costs
7. Cost-effectiveness in cardiac rehabilitation
8. Cardiac rehabilitation—cost analysis
9. Foundations of cost-effectiveness analysis for health and medical practices
10. Issues in quality-of-life measurement in clinical trials
11. Rehabilitation of the cardiac patient: a preview of tomorrow
12. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction
13. Utility, decision, and quality of life
14. Integrating economic evaluations and quality of life assessments
15. Social preferences for health states: an empirical evaluation of three measurement techniques
16. Utilities and quality-adjusted life years
17. Functional status versus utilities in survivors of myocardial infarction
18. Discussion: Torrance's “utility approach to measuring healthrelated quality of life”
19. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
20. Methods for quality adjustment of life years
21. Nonionic contrast media: economic analysis and health policy development
22. The cost-effectiveness of counseling smokers to quit
23. On JUMBO and “junkie” trials. A fumbled affair, a jungle, or the ultimate solution?
24. Cost-effectiveness of routine long-term beta adrenergic antagonist therapy following acute myocardial infarction
25. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension
26. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of heart disease
27. Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia
28. Cardiac rehabilitation: a supply-demand imbalance
29. Efficacy of cardiac rehabilitation; with emphasis on patients after myocardial infarction
30. The general health policy model: an integrated approach
31. Preferences for health outcomes comparison of assessment methods
32. Does cardiac rehabilitation increase survival after myocardial infarction?